BSE filing, NSE: NOVARTIND. Summary written from the filing by ALFA Finder's alert engine.
Evonile Pharma Ltd: key numbers
- Share price
- ₹1,719.85
- Market cap
- ₹4,246 Cr
- Revenue (annual)
- ₹354.3 Cr
- Net profit (annual)
- ₹93.18 Cr
- P/E (TTM)
- 43.4×Sector 47.2×
- Promoter holding
- 70.68%+0.00% QoQ
- FII holding
- 1.21%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Evonile Pharma Ltd
All →Evonile Pharma Investor Presentation: Key Takeaways
Q2 FY27 revenue fell 38% YoY to ₹56.1 cr, with a ₹77.5 cr net loss including ₹68 cr exceptional items. Transition from single-customer model to independent distribution continues.
Evonile Pharma Q2 FY27 Results: Net Loss of ₹77.5 Cr
Evonile Pharma posted a ₹775.4 million quarterly loss for September 2026 versus profit a quarter earlier. Exceptional items of ₹682.6 million drove the half-year pre-tax loss.
- Key figure
- Net loss ₹77.5 Cr
Novartis India Board Meeting Date
Evonile Pharma will hold a board meeting on November 4, 2026 to approve the rights issue letter of offer. BSE granted in-principle approval for the rights issue.
Novartis India Management Change
Evonile Pharma (formerly Novartis India) appointed Mr. Gagan Sharma as President – Specialty Business and Senior Management Personnel effective October 26, 2026. The filing is a Regulation 30 senior management appointment intimation.
Novartis India Other Announcement
Novartis India Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations. This is a routine periodic disclosure.
Novartis India Annual General Meeting
Evonile Pharma (fka Novartis India) issued a postal ballot notice for shareholder votes on ESOP 2026 grant to the MD & CEO and creation of charge on assets. E-voting runs 14 Oct–12 Nov 2026.
Other results update announcements
All →Multi Commodity Exchange of India Results Update
MCX reported H1FY27 consolidated revenue of ₹1,502 crore, up 100.8% YoY, and PAT of ₹868 crore. Q2FY27 PAT rose 130.8% YoY to ₹455 crore.
Shanti Gold International Results Update
Shanti Gold reported H1 FY27 revenue of Rs. 1,462.3 crore and PAT of Rs. 80.0 crore. Revenue doubled, but Q2 EBITDA margin compressed to 5.7%.
Aarti Drugs Results Update
Aarti Drugs reports Q2 FY27 revenue of ₹828.8 Crore and PAT of ₹82.8 Crore, up 83% YoY. Results reflect record quarterly EBITDA and margin expansion.
Fine Organic Industries Results Update
Fine Organic reports Q2 FY27 revenue of ₹729.4 Crore and PAT of ₹152.1 Crore, up 40.1%. Results show strong year-on-year growth across revenue, EBITDA and profit.
Jyoti Structures Results Update
Jyoti Structures reported standalone Q2 FY27 total income up 60.2% to Rs 248.57 crore and PAT of Rs 15.37 crore. The order book stood at Rs 4,219 crore as of September 30, 2026.
Samhi Hotels Results Update
SAMHI Hotels reported unaudited Q2 and H1 FY27 results, with Q2 total income up 15.6% to Rs 3,427 Mn and PAT of Rs 411 Mn. Management highlighted same-store growth and a pipeline of about 1,700 new rooms through FY2031.